Conference abstractPublished 20 Aug 2018
Institutional experiences in clinical evaluation of biosimilars
NIHR Clinical Research Network, UK
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Uptake and acceptance of biosimilar medicines in the UK is accelerating and will continue to do so as the NHS (National Health Service) has recently introduced a new commissioning framework for biologic and biosimilar medicines. But there is still work to do to optimize the potential cost-saving bene ts of biosimilar throughout the NHS. This presentation describes how unique challenges in the UK to the delivery of biosimilar clinical trials have been identi ed and overcome. It demonstrates how our biosimilar research delivery strategy was put into practice and will use case study examples and project outputs to illustrate the results. Finally, it will showcase the UK’s ongoing campaign which continues to drive changes in attitudes, appetite and acceptance for biosimilars in the UK National Health Service.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Divya Chadha Manek”